Association of pre-existing cardiovascular disease with cardiovascular and clinical outcomes in patients receiving immune checkpoint inhibitors
A retrospective study of 608 patients in Saudi Arabia found that pre-existing cardiovascular disease is a significant independent predictor of cardiovascular events in cancer patients receiving immune checkpoint inhibitors. The findings suggest that patients with baseline heart conditions face a substantially higher risk of complications during immunotherapy.
Why it matters
As immunotherapy becomes a standard cancer treatment, identifying high-risk patients is crucial for managing potential life-threatening cardiovascular side effects.
Scientific Reports ( 2026 ) Cite this article
We’re sharing this article early to provide faster access to peer-reviewed, accepted research. It is citable and carries a permanent DOI. This version is subject to further edits and will be replaced automatically by the final Version of Record. All legal disclaimers apply.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in